Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bristol-Myers Squibb Company or Johnson & Johnson because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Bristol-Myers Squibb Company and Johnson & Johnson compare based on key financial metrics to determine which better meets your investment needs.

About Bristol-Myers Squibb Company and Johnson & Johnson

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Latest Pharmaceuticals and Bristol-Myers Squibb Company, Johnson & Johnson Stock News

As of April 27, 2026, Bristol-Myers Squibb Company had a $118.0 billion market capitalization, compared to the Pharmaceuticals median of $579.9 million. Bristol-Myers Squibb Company’s stock is up 8.2% in 2026, down 1.8% in the previous five trading days and up 18.67% in the past year.

Currently, Bristol-Myers Squibb Company’s price-earnings ratio is 16.7. Bristol-Myers Squibb Company’s trailing 12-month revenue is $48.2 billion with a 14.6% net profit margin. Year-over-year quarterly sales growth most recently was 1.3%. Analysts expect adjusted earnings to reach $6.262 per share for the current fiscal year. Bristol-Myers Squibb Company currently has a 4.4% dividend yield.

As of April 27, 2026, Johnson & Johnson had a $542.4 billion market cap, putting it in the 100th percentile of all stocks. Johnson & Johnson’s stock is up 11.2% in 2026, up 1.7% in the previous five trading days and up 45.45% in the past year.

Currently, Johnson & Johnson’s price-earnings ratio is 26.1. Johnson & Johnson’s trailing 12-month revenue is $96.4 billion with a 21.8% net profit margin. Year-over-year quarterly sales growth most recently was 9.9%. Analysts expect adjusted earnings to reach $11.575 per share for the current fiscal year. Johnson & Johnson currently has a 2.4% dividend yield.

How We Compare Bristol-Myers Squibb Company and Johnson & Johnson Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bristol-Myers Squibb Company and Johnson & Johnson’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Bristol-Myers Squibb Company and Johnson & Johnson Stock Value Grades

Company	Ticker	Value
Bristol-Myers Squibb Company	BMY	C
Johnson & Johnson	JNJ	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Bristol-Myers Squibb Company has a Value Score of 59, which is Average. Johnson & Johnson has a Value Score of 20, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Bristol-Myers Squibb Company or Johnson & Johnson has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Bristol-Myers Squibb Company or Johnson & Johnson is the better investment when it comes to value.

Bristol-Myers Squibb Company and Johnson & Johnson Growth Grades

Company	Ticker	Growth
Bristol-Myers Squibb Company	BMY	C
Johnson & Johnson	JNJ	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Bristol-Myers Squibb Company has a Growth Score of 43, which is Average. Johnson & Johnson has a Growth Score of 73, which is Strong.

The Growth Grade Winner: Johnson & Johnson

As you can clearly see from the Growth Grade breakdown above, Johnson & Johnson has a more attractive growth grade than Bristol-Myers Squibb Company. For investors who focus solely on how a company is growing relative to other companies in the same industry, Johnson & Johnson could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Bristol-Myers Squibb Company and Johnson & Johnson’s Momentum Grades

Company	Ticker	Momentum
Bristol-Myers Squibb Company	BMY	C
Johnson & Johnson	JNJ	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Bristol-Myers Squibb Company has a Momentum Score of 54, which is Average. Johnson & Johnson has a Momentum Score of 64, which is Strong.

The Momentum Grade Winner: Johnson & Johnson

As you can clearly see from the Momentum Grade breakdown above, Johnson & Johnson is considered to have stronger momentum compared to Bristol-Myers Squibb Company. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Johnson & Johnson could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Bristol-Myers Squibb Company and Johnson & Johnson Grades

In addition to Growth, Momentum and Value, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Bristol-Myers Squibb Company and Johnson & Johnson pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Bristol-Myers Squibb Company or Johnson & Johnson Stock?

Overall, Bristol-Myers Squibb Company stock has a Value Score of 59, Growth Score of 43 and Momentum Score of 54.

Johnson & Johnson stock has a Value Score of 20, Growth Score of 73 and Momentum Score of 64.

Comparing Bristol-Myers Squibb Company and Johnson & Johnson’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.